Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications.Axsome Therapeutics is building a portfolio of differentiated product candidates that address unmet medical needs. Some of our product candidates combine multiple mechanisms of action to produce novel medicines that address deficiencies of current approaches.
|Bank Name||Axsome Therapeutics, Inc.|
|Chairman||Dr. Herriot Tabuteau M.D.|
|CEO||Dr. Herriot Tabuteau M.D.|